Brokerages expect that Luminex Co. (NASDAQ:LMNX) will report earnings of $0.21 per share for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Luminex’s earnings, with estimates ranging from $0.18 to $0.22. Luminex posted earnings of $0.28 per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 25%. The firm is scheduled to issue its next quarterly earnings results on Monday, May 7th.
On average, analysts expect that Luminex will report full year earnings of $0.64 per share for the current year, with EPS estimates ranging from $0.57 to $0.70. For the next year, analysts anticipate that the company will post earnings of $0.81 per share, with EPS estimates ranging from $0.71 to $0.90. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Luminex.
Luminex (NASDAQ:LMNX) last posted its quarterly earnings results on Monday, February 12th. The medical instruments supplier reported $0.20 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.09 by $0.11. The firm had revenue of $78.20 million for the quarter, compared to analyst estimates of $77.33 million. Luminex had a return on equity of 8.48% and a net margin of 9.48%. The business’s quarterly revenue was up 8.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.11 EPS.
A number of analysts have recently weighed in on LMNX shares. BidaskClub upgraded Luminex from a “sell” rating to a “hold” rating in a research report on Friday, March 9th. BTIG Research began coverage on Luminex in a report on Friday, January 5th. They set a “buy” rating and a $24.00 price target for the company. Finally, William Blair reaffirmed a “market perform” rating on shares of Luminex in a report on Tuesday, February 13th. Four equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. Luminex presently has a consensus rating of “Buy” and an average target price of $22.33.
Several institutional investors and hedge funds have recently modified their holdings of LMNX. Creative Planning purchased a new stake in Luminex in the fourth quarter worth $198,000. UBS Asset Management Americas Inc. bought a new stake in Luminex during the fourth quarter valued at $206,000. Teacher Retirement System of Texas bought a new stake in Luminex during the fourth quarter valued at $270,000. Municipal Employees Retirement System of Michigan boosted its stake in Luminex by 63.6% during the third quarter. Municipal Employees Retirement System of Michigan now owns 15,430 shares of the medical instruments supplier’s stock valued at $314,000 after buying an additional 6,000 shares during the period. Finally, Waldron LP bought a new stake in Luminex during the fourth quarter worth about $330,000. 81.39% of the stock is owned by institutional investors.
Shares of NASDAQ LMNX opened at $21.07 on Thursday. Luminex has a 12 month low of $17.93 and a 12 month high of $22.42. The company has a market cap of $936.16, a PE ratio of 23.15, a price-to-earnings-growth ratio of 2.02 and a beta of 0.11.
The firm also recently declared a quarterly dividend, which will be paid on Friday, April 13th. Investors of record on Friday, March 23rd will be given a dividend of $0.06 per share. This represents a $0.24 dividend on an annualized basis and a dividend yield of 1.14%. The ex-dividend date is Thursday, March 22nd. Luminex’s payout ratio is 26.37%.
TRADEMARK VIOLATION NOTICE: “Luminex Co. (LMNX) Expected to Post Earnings of $0.21 Per Share” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/04/08/luminex-co-lmnx-expected-to-post-earnings-of-0-21-per-share.html.
Luminex Company Profile
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system.
Get a free copy of the Zacks research report on Luminex (LMNX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.